Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly nab-paclitaxel plus ramucirumab in previously treated advanced gastric or gastroesophageal junction adenocarcinoma
jRCTs031180061Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: progression-free survival. Started Jan 2019; status: completed.
02
Drugs
paclitaxelramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031180061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180061.